Hi! There was a common theme threaded through every conversation at this year’s MassBio State of Possible conference: Communications is the essential bridge between scientific advancement and human impact. Every session came back to the fact that how we share stories determines whether breakthroughs reach those who need them, and I’ve picked out some moments that really reiterated this message for me. When science meets storytellingBrad Loncar, founder of BiotechTV, shared a personal anecdote of a single interaction which highlighted how scientific progress and public awareness often move at different speeds: He'd recently heard about a sickle cell disease patient completely unaware of newly approved gene therapies. "We have a PR problem," Loncar observed, noting how public perception often fails to distinguish the complex ecosystem beneath the "big pharma" umbrella. The timeline translation challengeCigall Kadoch, Dana-Farber Cancer Institute investigator, Harvard Medical School associate professor, and scientific co-founder of Foghorn Therapeutics, spoke directly to the challenges of explaining the biopharma timeline to the general population. "Sharing with the public how long it takes" to develop treatments matters deeply, she emphasized, because our field's work is "rooted in complex biological concepts that are not always accessible to the general public." Her insights underscored how transparency about scientific processes builds crucial understanding. Nello Mainolfi, Kymera Therapeutics CEO, pushed this conversation further: "We have too many people between those who invent medicines and those who need them that obfuscate our message." His observation sparked discussions about rebuilding direct connections between scientific innovation and public understanding. "We cannot cry and complain," he noted. "It's an opportunity to say we want to be at the table explaining what we do." Community as the catalystThroughout the conference, moments of authentic connection became the most memorable catalysts for change. Bioversity graduate Lazaro Rivera, now at Foundation Medicine, captured this energy when sharing how "stepping outside our comfort zone" creates mind-blowing possibilities. His journey from training program to professional role embodied how community support transforms individual potential. And, during a Make-A-Wish segment, Brian Lane shared how community sustained his family through his son Mark "Swaggy's" journey: "We're okay because of two things: Mark and community... that feeling that we're part of something bigger than ourselves." His story illuminated how shared purpose gives meaning to both challenge and triumph. Communicating through changeThe most effective communicators at State of Possible demonstrated that connecting benchtop breakthroughs with bedside impact requires both scientific precision and emotional resonance. Against a backdrop of FDA reform discussions, HHS policy shifts, and market pressures, Governor Maura Healey's call to "continue to speak up, continue to advocate" resonated deeply. But former MassBio CEO and cystic fibrosis advocate Bob Coughlin, receiving the Henri A. Termeer Innovative Leadership Award, perhaps captured this connection most succinctly. Biotech, he said, “found him” because “this is the place where news is made... cures are found." His words remind everyone in life sciences that communication isn't peripheral to our mission – it's how scientific possibility becomes human reality. For me, these stories from State of Possible offered more than inspiration. They provide a blueprint for communicating through complexity, demonstrating how shared narratives move science forward for those waiting on what's next. If you attended the conference, we’d love to hear your thoughts and key takeaways – just reply to this email and let us know. Lynnea PS - This note is an abridged version of a longer blog post that you can read on MassBio's website here, along with more photos! |
Hi! The outcomes of the annual American Society of Clinical Oncology (ASCO) meeting will flood the media landscape with clinical updates, milestone announcements, and analyst notes. So biopharma comms pros and storytellers must understand how to stand out during one of healthcare’s most concentrated news moments. Enter the Q2 Media Minds Panel: Oncology Reporting and ASCO Coverage. “Top-Tier Perspective on ASCO and Beyond: How to Stand Out During Concentrated News Moments” is happening...
Hi! Last week, the T2B community tackled the topic of trust. In an intriguing and very candid Comm Convo led by speakers Kris Baum (former FDA, CDER), Mary Kosinski (FleishmanHillard), and Sarah Spencer (Vor Bio), we explored how the relationships we build shape our ability to lead, influence, and respond. With so many specific anecdotes and practical tips shared, it was hard to narrow down to just 10 key takeaways, but we managed it (barely!): Leverage science as your trust anchor. When...
Hi! We’re all about bringing together the most creative minds in biopharma in a bid to secure and enhance the future of our profession. One of the many ways we do this is through our roundtables, which are driven directly by members who specialize in, and are passionate about, key areas of biopharma communications. And the next discipline on that roster is patient advocacy and engagement. Everything you need to know about the Patient Advocacy and Engagement Roundtable This roundtable will...